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Abstract
Background  and  objectives:  Erythrocyte  morphology  changes  not  only  by  primary  hematological
diseases  but  also  by  systemic  inﬂammation,  ineffective  erythropoiesis  and  nutritional  deﬁcien-
cies. Red  blood  cell  distribution  width  (RDW)  is  a  parameter  reﬂecting  erythrocyte  morphology.
We aimed  to  investigate  the  relationship  of  RDW  with  chronic  obstructive  pulmonary  disease
(COPD) stages,  BODE  index  and  survival  in  COPD  patients.
Methods:  Medical  records  of  385  COPD  patients  between  July  2004  and  November  2005  were
studied retrospectively.  Demographic  features,  BODE  index  factors  and  oxygen  saturation  were
recorded. Survival  analysis  of  all  patients  by  2014  was  performed.  Measured  RDW  values  at  the
time of  the  inclusion  were  evaluated.
Results:  Mean  age  of  the  patients  was  65.6  ±  9.6  years.  Distribution  of  the  COPD  stages  of  the
patients  were  stage  1:  16%,  stage  2:  52%,  stage  3:  26%,  stage  4:  6%.  RDW  was  found  signiﬁcantly
different  between  stages.  The  highest  RDW  was  observed  in  the  very  severe  stage  (p  <  0.001).
Median of  BODE  index  was  1  (0--3).  As  the  BODE  index  increased  RDW  also  increased  (p  <  0.001).
When the  patients  were  grouped  according  to  the  laboratory  upper  limit  of  RDW,  survival  rate
was 31%  in  the  RDW  >14.3%  group  and  75%  in  the  RDW  <14.3%  group.
Conclusion:  The  variability  in  the  size  of  circulating  erythrocytes  increases  as  the  COPD  severity
progresses.  Therefore,  a  simple  and  noninvasive  test,  such  as  RDW,  might  be  used  as  a  biomarker
in the  evaluation  of  the  severity  of  COPD.  At  the  same  time,  there  seems  to  be  a  correlation
between the  survival  of  COPD  patients  and  RDW.
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Introduction
Chronic  obstructive  pulmonary  disease  (COPD)  is  deﬁned  as  a
preventable  and  treatable  disease  characterized  by  usually
progressive  persistent  airﬂow  limitation  that  is  associated
with  an  enhanced  chronic  inﬂammatory  response  in  the  air-
ways  and  the  lung  to  noxious  particles  or  gases.1 However,
it  is  still  the  ﬁfth  leading  cause  of  death  and  estimated  to
be  the  third  in  2030  worldwide.2 Currently,  COPD  has  been
accepted  as  a  component  of  systemic  inﬂammatory  syn-
drome  and  the  mortality  mostly  depends  on  cardiovascular
diseases  rather  than  respiratory  failure.3 Possible  explana-
tions  for  the  high  cardiovascular  morbidity  and  mortality
observed  in  COPD  patients  are  high  smoking  prevalence,  diet
and  sedentary  life  style  as  well  as  systemic  inﬂammation  due
to  oxidative  stress  and  chronic  hypoxia.4,5
The  red  cell  distribution  width  (RDW)  is  a  routine  labo-
ratory  parameter  that  indicates  the  variability  in  the  size
of  circulating  erythrocytes.  The  main  area  which  the  RDW
is  used  is  the  differential  diagnosis  of  microcytic  anemia.
It  has  been  deﬁned  as  a  prognostic  tool  in  different  clinical
settings  such  as  pulmonary  arterial  hypertension,  congestive
heart  failure  and  coronary  heart  disease.6--8 It  has  also  been
reported  as  a  powerful  predictor  of  mortality  in  general  pop-
ulation  and  older  adults.9,10 Increased  RDW  values  have  been
reported  to  be  related  with  underlying  chronic  inﬂammation
which  promotes  red  blood  cell  membrane  deformability  and
changes  in  erythropoiesis.11
Accordingly,  we  hypothesized  that  systemic  inﬂammation
may  be  the  common  link  between  increased  RDW  values
and  mortality  in  patients  with  COPD.  Therefore  we  aimed  to
study  the  relationship  between  RDW  and  airﬂow  limitation
severity  stages,  BODE  index  and  survival  in  COPD  patients.
Methods
We  conducted  a  retrospective  cohort  study  in  patients  diag-
nosed  as  COPD  by  global  initiative  for  chronic  obstructive
lung  disease  (GOLD)  criteria  between  July  2004  and  Novem-
ber  2005  to  observe  the  9-year  survival  rate.1 The  inclusion
criteria  was:  being  on  stable  state  (no  history  of  hospitaliza-
tion  or  admission  to  an  emergency  department  for  at  least
8  weeks),  absence  of  cancer  history,  connective  tissue  dis-
orders,  inﬂammatory  bowel  disease,  hematological  system
diseases,  blood  transfusion  and  anti-inﬂammatory  drug  (sys-
temic  steroids,  immunosuppressive  drugs)  usage  in  the  last
2  months.  In  January  2014  we  searched  for  the  survival  of
these  patients  in  the  registry  to  evaluate  9-year  survival
rate.  We  used  the  hospital  automation  software  which  was
integrated  with  the  national  population  system  to  determine
the  deaths.
Demographic  features  and  medical  history  including
comorbid  diseases  such  as  hypertension,  diabetes  melli-
tus,  cardiovascular  disease  and  smoking  status  of  the  study
population  were  recorded.  Six-minute  walk  test  (6MWT),
pulmonary  function  tests  (PFT),  BODE  index  and  complete
blood  count  results  at  the  time  of  the  inclusion  (July  2004
and  November  2005)  were  also  collected  from  the  medical
records  of  the  patients.
It  would  be  better  to  use  the  composite  COPD  assess-
ment  index  recommended  by  GOLD  since  2011.  That  was  not
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ossible  because  at  the  time  of  the  study,  dyspnea  scores  and
he  number  of  exacerbations  in  the  previous  year  were  not
ccessible.
ulmonary  function  tests
FTs  were  performed  with  Jaeger  Master  Screen  Pneumo
452˙I  device  by  a  single  technician  between  July  2004  and
ovember  2005.  The  best  test  among  the  three  consecu-
ive  ones  was  accepted.  FEV1 (Forced  expiratory  volume  in
 s),  FVC  (Forced  vital  capacity),  FEV1/FVC  (percentage  of
VC  expelled  in  the  ﬁrst  second  of  a  forced  expiration)  were
easured  according  to  American  Thoracic  Society  criteria.12
he  airﬂow  limitation  severity  staging  was  done  according
o  GOLD  2015.1
aboratory  measurements
lood  samples  obtained  between  July  2004  and  November
005  were  evaluated.  RDW  normal  range  was  between  11.8%
nd  14.3%  in  our  laboratory.
ix-minute  walk  test
MWT  was  performed  in  a  corridor  of  35  m  at  the  time  of
iagnosis.  Patients  were  motivated  to  walk  as  fast  as  they
ould.  Oxygen  saturation  was  measured  before  and  after  the
est  and  the  distance  walked  was  recorded.13
ODE  index
ODE  index  was  calculated  according  to  body  mass  index
BMI),  FEV1,  6MWT,  modiﬁed  medical  research  council  dys-
nea  scale  (MMRC)  at  the  time  of  diagnosis.14
xygen  saturation
xygen  saturation  was  measured  by  pulse  oxymeter  at  the
ime  of  diagnosis  (Plusmed).
tatistical  analyses
ata  were  analyzed  by  SPSS  15.0  package  program.  The  fre-
uencies  of  the  results  were  expressed  according  to  the
ispersion  properties  of  data.  Variables  were  compared  by
npaired  t  tests  for  continuous  data  and  Mann  Whitney  U-
est  for  nonparametric  data.  Chi-square  analysis  was  used
or  categorical  data.  Spearman  and  Pearson  correlation  tests
ere  used  for  correlation  analysis.  A  p  value,  <0.05  was
onsidered  signiﬁcant.
Survival  analysis  was  performed  thereafter  grouping
atients  according  to  the  laboratory  upper  limit  of  RDW.  The
atients’  inclusion  date  in  the  study  was  considered  as  the
rst  day.  The  last  check  date  or  the  discharge  date  was  con-
idered  as  the  last  day  on  survival  analysis.  Kaplan--Meier
urvival  analysis  was  performed  for  univariate  survival  anal-
sis.  Multivariate  analysis  for  survival  rates  were  further
erformed  by  Cox  proportional  hazards  regression  to  adjust
or  age,  comorbid  diseases,  FEV1 and  6MWT.
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Table  1  Demographic  characteristics  of  the  study
population.
n  (%)
Gender
Male  338  (88)
Female  47  (12)
GOLD stages
Stage  1  64  (16)
Stage 2  200  (52)
Stage 3  99  (26)
Stage 4 22  (6)
Smoking  status
Non-smoker  50  (13)
Smoker  125  (32)
Ex smoker  210  (55)
Comorbidity
Yes 226  (59)
CVSD 214  (56)
DM 33  (9)
Others  122  (32)
No 159  (41)
Mortality  cause
Cancer  28  (9)
COPD 30  (8)
Pneumonia  20  (5)
CVSD 31  (10)
Renal failure  5  (1)
Neurologic  disorder  2  (1)
BODE index  (median/min-max)  1.0  (0.0--10.0)
COPD: chronic obstructive pulmonary disease, CVS: cardio-
vascular system disorders, DM: diabetes mellitus, Others:
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Table  2  RDW  levels  according  to  GOLD  stages  (p  <  0.001).
Mean  RDW  (%)
GOLD  stages
Stage  1  13.5
Stage 2  13.9
Stage 3  14.4
Stage 4  15.7
RDW: red cell distribution width, COPD: chronic obstructive pul-
monary disease.
Table  3  Correlation  of  RDW  with  functional  and  demo-
graphic parameters.
RDW  correlation  r  p
6MWT  −0.279  <0.001
%FEV1 −0.290  <0.001
%FVC −0.285  <0.001
FEV1/FVC  −0.206  <0.001
%FEF 25--75  −0.303  <0.001
%PEF −0.227  <0.001
Oxygen saturation  −0.260  <0.001
BMI −0.059  0.247
Age 0.182  <0.001
BODE index  0.407  <0.001
GOLD stage  0.403  <0.001
6MWT: 6 min walk test, FEV1: forced expiratory volume in 1 s,
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and  smoking  and  questioned  the  direct  effects  of  RDW  onneuromuscular system disorders and renal diseases, BODE: body
mass index, airﬂow obstruction, dyspnea and exercise capacity.
Ethics  approval  was  obtained  from  Dokuz  Eylul  University
aculty  of  Medicine  Local  Ethics  Committee  and  we  have
igned  informed  consent  from  all  patients.
esults
hree  hundred  eighty  ﬁve  COPD  patients  were  included  in
he  analysis.  Mean  age  of  the  study  population  was  65.6  ±  9.6
ears.  Most  of  the  patients  were  males,  ex-smokers  and  had
omorbidities  (Table  1).
Distribution  of  the  COPD  stages  of  the  patients  were  stage
:  16%,  stage  2:  52%,  stage  3:  26%,  stage  4:  6%.  Median  of
he  BODE  index  was  1  (0--3).  Mean  RDW  levels  were  found
o  be  increasing  with  the  severity  of  COPD  (Table  2).
RDW  was  inversely  correlated  with  the  6  min  walk  test,
ulmonary  functional  parameters  and  oxygen  saturation.
here  was  also  a  mild  association  with  age,  GOLD  stage  and
 moderate  correlation  with  BODE  index  (Table  3).
Pulmonary  functional  parameters,  6MWT  distance  andxygen  saturation  were  lower  for  patients  with  an  elevated
DW,  while  age,  smoking  intensity  and  BODE  index  were
igher  (Table  4).
p
R
aFVC: forced vital capacity, FEF 25--75: forced expiratory ﬂow
rate 25--75%, PEF: peak expiratory ﬂow, BMI: body mass index,
RDW: red cell distribution width.
Median  follow  up  time  for  the  study  population  was  84.5
onths  (2--114  months).  The  overall  9-year  survival  rate
f  the  study  population  was  61%.  When  the  patients  were
ivided  into  2 groups  according  to  RDW  the  9-year  survival
ate  was  75%  for  patients  with  normal  RDW  (≤14.3%)  and
1%  for  patients  with  an  elevated  RDW  (>14.3%)  (p  <  0.001)
Fig.  1).  On  multivariate  analysis,  when  adjusted  for  poten-
ial  confounders,  age  and  6MWT  were  found  to  be  associated
ith  survival  (Table  5).
iscussion
OPD  is  a  chronic  respiratory  disease  with  signiﬁcant  mor-
ality  and  morbidity.  Elevated  levels  of  RDW  have  been
eported  to  be  related  with  cardiovascular  mortality.4
onsidering  RDW  as  a  mortality  predictor,  in  this  study
e  investigated  the  relationship  between  RDW  and  air-
ow  limitation  severity  stages,  BODE  index  and  survival  in
OPD  patients.  We  found  increased  RDW  levels  associated
ith  COPD  severity  and  also  observed  a  higher  mortality  in
atients  with  increased  RDW  levels.
A  recent  population  based  study  reported  a  negative
nd  independent  association  of  RDW  with  lung  function
fter  eliminating  the  effects  of  potential  confounders.15 The
tudy  could  not  determine  any  interaction  between  RDWulmonary  functions.  However,  in  another  study,  smokers
DW  levels  were  found  to  be  higher  than  the  ones  associ-
ted  with  non-smokers.16 In  another  study  investigating  the
COPD  severity  prediction  with  RDW  199
Table  4  Functional  and  demographic  parameters  of  the  study  population  according  to  upper  limit  of  RDW  values.
All  patients  RDW  ≤  14.3  RDW  >  14.3  p
Age  65.6± 64.4  68.0  =0.001
FEV1 (L)  1.66  1.80  1.34  <0.001
%FEV1 60.2  64.6  50.5  <0.001
FVC (L)  2.86  3.04  2.45  <0.001
%FVC 80.8  85.1  71.2  <0.001
FEV1/FVC  57.2  58.7  53.9  <0.001
PEF (L)  4.79  5.1  4.1  <0.001
%FEF 25/75  26.1  28.7  20.3  <0.001
Smoking (packyears) 56.0  52.5  63.3  =0.005
Smoking beginning  age 17.8  18.2  16.8  =0.02
BMI 25.4  25.6  24.9  =0.09
6MWT (meters)  435  453  393  <0.001
Oxygen saturation  (%)  96.0  96.4  95.1  <0.001
BODE index  1.83  1.32  2.98  <0.001
Survival (months)
Alive  236  n:  199  75%  n:  37  31%  <0.001
Exitus 149  n:  66  25%  n:  83  69%
FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, FEF 25--75: forced expiratory ﬂow rate 25--75%, PEF: peak expiratory
ﬂow, BMI: body mass index, 6MWT: 6 min walk test. BODE: body mass index, airﬂow obstruction, dyspnea and exercise capacity. Data
were expressed as mean ± standard deviation.
Time (months)
120.00100.0080.0060.0040.0020.000.00
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Figure  1  Unadjusted  --  Kaplan--Meier  curve  for  long-term  sur-
Table  5  Impact  of  RDW  and  potential  confounders  on
survival.
Odds
ratio
95%  conﬁdence
interval
p  value
FEV1 0.529  0.375--0.747  <0.001
RDW 1.222  1.153--1.295  <0.001
6MWT 0.998  0.997--1.000  0.007
Age 1.055 1.033--1.077  <0.001
Comorbidities  1.430  1.004--2.036  <0.01
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rvival  according  to  red  cell  distribution  width  (RDW)  groups  in  the
entire  cohort  of  patients  (p  <  0.001  by  log-rank  test).
prognostic  usefulness  of  RDW  in  idiopathic  pulmonary  ﬁbro-
sis,  the  authors  found  that  the  patients  with  lower  FEV1 and
lower  diffusing  capacity  had  higher  RDW  and  concluded  that
RDW  was  an  independent  prognostic  information  at  baseline
and  follow-up.17The  results  of  our  study  also  demonstrated  that  pul-
monary  function  test  parameters  were  negatively  associated
with  RDW.  This  ﬁnding  was  concordant  with  the  high  RDW
C
e
rFEV1: forced expiratory volume in 1 s, RDW: red cell distribution
width, 6MWT: 6 min walk test.
evels  we  observed  in  severe  COPD  stages,  especially  in
he  very  severe  group.  We  also  detected  a relationship
etween  smoking  intensity  and  RDW  levels,  which  might  be
ue  to  hypoxemia  related  erythropoiesis.  The  correlation
f  the  oxygen  saturation  and  RDW  levels  also  supports  this
ypothesis.
BODE  index,  which  has  been  found  to  be  related  with
ortality  in  COPD,  was  associated  with  RDW  in  our  study.
ccording  to  our  knowledge,  the  relationship  between  RDW
nd  exercise  capacity  in  COPD  patients  has  not  been  shown
efore.  In  this  study  elevated  RDW  levels  were  found  signiﬁ-
antly  related  with  poor  exercise  capacity  in  COPD  patients.
here  is  a  limited  number  of  studies  investigating  the  asso-
iation  of  BODE  index  with  systemic  inﬂammatory  markers
ther  than  RDW.  A  relation  with  C  reactive  protein  and
eptin  has  been  reported  while  tumor  necrosis  factor  alfa
nd  interleukin  6  were  found  to  be  unrelated.18--20 In  a
ecent  study  investigating  the  prognostic  value  of  RDW  in
OPD,  cardiac,  respiratory,  and  hemotological  status  were
valuted  and  RDW  was  found  to  be  correlated  with  C
eactive  protein,  pulmonary  arterial  hypertension  and  right
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100  
entricular  dysfunction.21 As  we  found  increased  RDW  lev-
ls  in  severe  COPD  similarly,  we  think  that  RDW  could  also
e  considered  as  a  prognostic  systemic  inﬂammatory  marker
n  COPD.
The  independent  association  between  RDW  and  survival
as  been  described  for  a  broad  spectrum  of  cardiovascu-
ar  and  pulmonary  disease  such  as  pulmonary  hypertension,
cute  pulmonary  embolism,  idiopathic  pulmonary  ﬁbrosis
nd  even  for  COPD.6,17,21,22 The  underlying  mechanisms
or  the  association  between  the  RDW  and  mortality
re  currently  unknown.  Nutritional  deﬁciencies,  comor-
id  diseases,  hematological  aberrations  and  impaired  renal
unctions  occurring  in  the  course  of  chronic  cardiopul-
onary  diseases  may  result  in  subtle  anemia,  reﬂected
y  increased  RDW.8,23--25 Elevated  RDW  values  may  also  be
ssociated  with  low  grade  inﬂammation  that  is  present  in
hronic  respiratory  diseases.  Inﬂammation  induces  changes
n  erythropoiesis,  erythrocyte  half-life,  and  erythrocyte
embrane  deformability.22 Accordingly,  we  observed  a
ower  survival  rate  in  COPD  patients  who  have  elevated  RDW
evels.
The  limitations  of  the  study  include  a  relatively  long
eriod  of  observation  of  survival  rates,  as  well  as  not
iscriminating  respiratory  system  mortality  from  all-cause
ortality  due  to  lack  of  data.  This  might  be  related  to  the
igh  rates  of  mortality  we  observed  in  our  cohort  of  COPD
atients  at  early  stages  of  the  disease.  Another  restriction
s  the  lack  of  a  control  group  with  similar  demographics  but
ithout  COPD  to  better  demonstrate  the  effect  of  the  dis-
ase  on  RDW.  It  would  also  be  better  to  use  the  composite
OPD  assessment  index  recommended  by  GOLD  since  2011.
hat  was  not  possible  because  at  the  time  of  the  study,  dys-
nea  scores  and  the  number  of  exacerbations  in  the  previous
ear  were  not  accessible.
onclusion
n  conclusion,  we  demonstrated  that  elevated  RDW  levels
n  patients  with  COPD  were  associated  with  disease  severity
nd  lower  survival  rates.  Increased  RDW  levels  might  be  an
ndicator  of  hypoxemia,  underlying  inﬂammation  and  oxida-
ive  stress  in  COPD  patients.  Therefore,  an  inexpensive  and
imple  laboratory  parameter,  such  as  RDW,  could  be  con-
idered  as  a  biomarker  in  the  evaluation  of  the  severity  of
OPD.
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